Recent Updates

This is where you will find information on the latest updates to the National Clinical Terminology Service products and resources. The details of any changes are included in the relevant release note.

/library/DH_3522_2021_ClinicalTerminology_SNOMEDCT-AU_ReleaseNote_v20210930.pdfSNOMED CT-AU Release Note 30 September 2021
/library/DH_3508_2021_NCTS_DocumentLibraryReleaseNote_v2.28.pdfNCTS Document Library Release Note v2.28
/library/DH_3319_2020_RCPA_PathologyTerminologyandInformationModels_ReleaseNote_v1.4.pdfRCPA Pathology Terminology and Information Models Release Note v1.4
/library/DH_3467_2021_RCPA_StructuredPathologyReportingofCancerFHIRReferenceSets_ReleaseNote_v1.0.pdfRCPA Structured Pathology Reporting of Cancer FHIR Reference Sets Release Note v1.0

ACT Reportable Schedule 4 medications reference set (added September 2021)

Produced by ACT Health, the ACT Reportable Schedule 4 medications reference set supports the identification of the AMT TPUU, CTPP, MPP and MPUU concepts associated with Schedule 4 medicines that are monitored by ACT Health Canberra Script Real-Time Prescription Monitoring (RTPM) solution. This reference set can be used by applications to identify Schedule 4 medicines that are to be monitored in support of the ACT Health Canberra Script system’s requirements. 

The full description of the above reference set can be viewed by selecting it within Reference Sets from the ACCESS tab.

Vaccination Recommendation Status reference set (added August 2021)

The Vaccination recommendation status reference set supports the recording of vaccination statuses for vaccine administration recommendations. This reference set can be used within any implementation that records vaccination statuses as part of vaccine administration recommendations.

NT Reportable Schedule 4 medications reference set (added June 2021)

The Northern Territory Reportable Schedule 4 medications reference set supports the identification of the AMT TPUU, CTPP, MPUU and MPP concepts that are reportable within the Northern Territory. This reference set can be used by applications to identify reportable Schedule 4 medications that are to be monitored in support of the Northern Territory Government Department of Health NTScript system’s requirements.

List of Excluded Medicinal Items reference set (added May 2021)

The List of Excluded Medicinal Items reference set supports the identification of AMT MPUU and MPP concepts associated with the List of Excluded Medicinal Items (LEMI) under The National Health (Pharmaceutical Benefits) Amendment (Active Ingredient Prescribing) Regulations 2019 and The Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019. This reference set can be used by prescribing software vendors to identify medicinal items listed on the Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme that are excluded from the Active Ingredient Prescribing requirements.

RCPA – Structured Pathology Reporting of Cancer FHIR Reference Sets (added May 2021)

This new bundle contains draft FHIR reference set resources developed and owned by the Royal College of Pathologists of Australaisa (RCPA), and includes:

  • RCPA SPRC Cervical Cancer FHIR Reference Set dv001
  • RCPA SPRC Colorectal Cancer FHIR Reference Set dv001
  • RCPA SPRC Endometrial Cancer FHIR Reference Set dv001
  • RCPA SPRC Carcinoma of the Ovary, Fallopian Tube and Primary Peritoneal Site FHIR Reference Set dv001
  • RCPA SPRC Polypectomy and Local Resections of the Colorectum FHIR Reference Set dv001

For more information and to access these resources please refer to the RCPA – Structured Pathology Reporting of Cancer FHIR Reference Sets Release Note in the RCPA section from the ACCESS tab.

NSW Reportable Schedule 4 reference set (added February 2021)

This newly released reference set supports systems with the identification of the AMT Trade Product Unit of Use (TPUU), Containered Trade Product Pack (CTPP), Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts that are reportable within New South Wales for Real Time Reporting (RTR) and Real Time Prescription Monitoring (RTPM) requirements. 

This reference set complements the existing reportable Schedule 4 reference sets and the Schedule 8 medications reference set.


Black Triangle Scheme reference set (added December 2020)

This newly release reference set supports the identification of AMT Trade Product Unit of Use (TPUU) and Containered Trade Product Pack (CTPP) concepts that are associated with medicines where reporting adverse events are encouraged under the Black Triangle Scheme run by the Therapeutic Goods Administration. This reference set can be used by prescribing and dispensing software vendors to identify medications where reporting of adverse events is encouraged under the Black Triangle Scheme. Further details be found in the SNOMED CT-AU Development Approach for Reference Sets v3.4.

List of Medicines for Brand Consideration reference set (added September 2020)

This reference set has been updated to include additional medicines as notified by the Australian Government Department of Health. This reference set enables software vendors to identify AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC).

COVID-19 concepts

The following list contains some of the SNOMED CT COVID-19 specific concepts available including those added specifically to the SNOMED CT-AU release. They are displayed below as concept ID |Preferred Term| and grouped according to their SNOMED CT concept hierarchy. You can view any additional concepts and synonyms in the Shrimp Terminology Browser.
Recent additions from the July 2021 SNOMED International release can be viewed in the SNOMED CT-AU September 2021 release note. If you have suggestions for new concepts or synonyms, please complete our online request form (preferred) or send your content request to help@digitalhealth.gov.au.

Clinical finding

840539006 |COVID-19|
1454671000168104 |Recent travel to high risk COVID-19 region|
1465981000168100 |Bilateral interstitial pneumonia| added May 2020
1466021000168105 |Concern about exposure to COVID-19| added May 2020
1466151000168103 |More than two diffuse B-lines on ultrasound of lung| added May 2020

Situation

840544004 |Suspected COVID-19|

Event

840546002 |Exposure to COVID-19|

Organism

840533007 |SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)|

Procedure

840534001 |COVID-19 vaccination|
1454651000168108 |COVID-19 serology|
1454581000168100 |Bronchoalveolar lavage fluid COVID-19 nucleic acid assay|
1454561000168109 |Sputum COVID-19 nucleic acid assay|
1454491000168101 |Oropharyngeal swab COVID-19 nucleic acid assay|
1454411000168105 |Nasopharyngeal swab COVID-19 nucleic acid assay|
1454401000168107 |Home isolation|
1462681000168102 |Rapid COVID-19 antibody detection test|
1462701000168104 |COVID-19 IgM measurement|
1462741000168102 |COVID-19 IgG measurement|
1466171000168107 |ARDSNet Mechanical Ventilation Protocol| added May 2020
1466161000168101 |Permissive hypercapnia ventilation| added May 2020
1466191000168108 |Pleural fluid COVID-19 nucleic acid assay| added May 2020
1466181000168105 |Saliva COVID-19 nucleic acid assay| added May 2020
1480481000168103 | COVID-19 viral culture | added July 2020

Environment

1454661000168105 |COVID-19 Clinic and Testing Centre|

Substance

840536004 |Antigen of SARS-CoV-2|
840535000 |Antibody to SARS-CoV-2|

Australian Medicines Terminology

1480881000168101 | Veklury 100 mg powder for injection, 1 vial | added July 2020
1480791000168108 | Veklury 100 mg/20 mL injection, 20 mL vial | added July 2020


1525001000168109 | BNT162b2 mRNA | added February 2021
1525021000168100 | COVID-19 mRNA vaccine | added February 2021
1525031000168102 | COVID-19 mRNA vaccine injection, 0.45 mL vial | added February 2021
1525051000168108 | COVID-19 mRNA vaccine injection, 195 x 0.45 mL vials | added February 2021
1525011000168107 | Comirnaty | added February 2021
1525041000168106 | Comirnaty Multidose injection, 0.45 mL vial | added February 2021
1525061000168105 | Comirnaty Multidose injection, 195 x 0.45 mL vials | added February 2021
1525071000168104 | Comirnaty Multidose injection, 195 x 0.45 mL vials | added February 2021


1527281000168103 | ChAdOx1-S viral vector | added February 2021
1527311000168101 | COVID-19 viral vector vaccine | added February 2021
1527321000168108 | COVID-19 viral vector vaccine, 5 mL vial | added February 2021
1527341000168102 | COVID-19 viral vector vaccine, 10 x 5 mL vials | added February 2021
1527271000168101 | COVID-19 Vaccine (AstraZeneca) | added February 2021
1527331000168106 | COVID-19 Vaccine (AstraZeneca) Multidose injection, 5 mL vial | added February 2021
1527351000168100 | COVID-19 Vaccine (AstraZeneca) Multidose injection, 10 x 5 mL vials | added February 2021
1527361000168103 | COVID-19 Vaccine (AstraZeneca) Multidose injection, 10 x 5 mL vials | added February 2021

1565211000168109 | elasomeran | added August 2021
1565221000168102 | elasomeran | added August 2021
1565231000168104 | elasomeran 200 microgram/mL injection, vial | added August 2021
1565251000168105 | elasomeran 200 microgram/mL injection, 10 x 5 mL vials | added August 2021
1565201000168106 | Spikevax | added August 2021
1565241000168108 | Spikevax Multidose 200 microgram/mL injection, 5 mL vial | added August 2021
1565261000168107 | Spikevax Multidose 200 microgram/mL injection, 10 x 5 mL vials | added August 2021
1565271000168101 | Spikevax Multidose 200 microgram/mL injection, 10 x 5 mL vials | added August 2021

1527271000168101 | Vaxzevria
1530521000168101 | Vaxzevria Multidose injection, 4 mL vial
1527331000168106 | Vaxzevria Multidose injection, 5 mL vial
1530541000168107 | Vaxzevria Multidose injection, 10 x 4 mL vials
1527351000168100 | Vaxzevria Multidose injection, 10 x 5 mL vials
1530551000168109 | Vaxzevria Multidose injection, 10 x 4 mL vials
1527361000168103 | Vaxzevria Multidose injection, 10 x 5 mL vials

By operation of the Public Governance, Performance and Accountability (Establishing the Australian Digital Health Agency) Rule 2016, on 1 July 2016, all the assets and liabilities of NEHTA will vest in the Australian Digital Health Agency. In this website, on and from 1 July 2016, all references to “National E-Health Transition Authority” or “NEHTA” will be deemed to be references to the Australian Digital Health Agency.